We conducted a cross-sectional survey to assess the prevalence of physical pain in Japanese major depressive disorder (MDD) and schizophrenia (SZ) patients as well as in healthy controls (HCs). We also examined the association between their psychopathology and characteristics of pain according to a face-to-face survey by an experienced psychiatrist and psychologist. We analyzed 233 HCs, 94 MDD patients, and 75 SZ patients using the McGill Pain Questionnaire (MPQ) and SF-8 (all participants), the Hamilton Depression Rating Scale 21 items (MDD patients), and the Positive and Negative Symptom Scale (SZ patients). Although MDD patients experienced more pain than HCs, there was no difference in the prevalence of pain between SZ patients and HCs. Moreover, HCs with pain did not have higher SF-8 total scores than those without pain, whereas both MDD and SZ patients with pain had higher SF-8 total scores than those without pain. The severity of psychopathology in MDD and SZ patients was also positively associated with both the prevalence of pain and MPQ scores. MPQ scores were also associated with positive symptoms in SZ patients. Considering these results, physicians need to query MDD patients about physical pain during examination if they are to ensure a favorable and quick response to treatment. The severity of positive symptoms (i.e., clinical status) in SZ patients might also be associated with pain sensitivity, and warrants further investigation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.comppsych.2015.02.004 | DOI Listing |
Brain Behav Immun Health
February 2025
Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, University of Eastern Piedmont, 28100, Novara, Italy.
Major Depressive Disorder (MDD) is a widespread psychiatric condition impacting social and occupational functioning, making it a leading cause of disability. The diagnosis of MDD remains clinical, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, as biomarkers have not yet been validated for diagnostic purposes or as predictors of treatment response. Traditional treatment strategies often follow a one-size-fits-all approach obtaining suboptimal outcomes for many patients who fail to experience response or recovery.
View Article and Find Full Text PDFNiger Med J
January 2025
Department of Physiology, RUHS College of Medical Sciences, India.
Background: Previous research has shown that Major Depressive Disorder (MDD) is accompanied by severe impairments in cognitive and autonomic processes, which may linger even when mood symptoms recover. This study aimed to analyse the relationship between depression severity, as measured by the Hamilton Depression Rating Scale (HAM-D), and how it affects heart rate variability (HRV) and cognitive function in patients with Major Depressive Disorder (MDD).
Methodology: The cross-sectional study was conducted at RUHS College of Medical Sciences and Associated Hospitals, Jaipur, from July 2022 to January 2023 on 90 subjects having major depressive disorder (MDD) of either sex in the 20-40 age group using the Hamilton score for depression (HAM D), Heart Rate Variability (HRV) measurements, and a battery of cognitive tests.
BMC Psychiatry
January 2025
West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China.
The current DSM-oriented diagnostic paradigm has introduced the issue of heterogeneity, as it fails to account for the identification of the neurological processes underlying mental illnesses, which affects the precision of treatment. The Research Domain Criteria (RDoC) framework serves as a recognized approach to addressing this heterogeneity, and several assessment and translation techniques have been proposed. Among these methods, transforming RDoC scores from electronic medical records (EMR) using Natural Language Processing (NLP) has emerged as a suitable technique, demonstrating clinical effectiveness.
View Article and Find Full Text PDFTher Innov Regul Sci
January 2025
Bayer AG, Pharmaceuticals R&D, Bayer AG, Muellerstr. 178, 13342, Berlin, Germany.
Medicine is increasingly supported by software, with digital health technologies offering innovative ways to capture insights and drive therapies. Globally, medical device software must follow regulatory processes based on risk classification. The introduction of MDR represents a significant shift in risk-based classification for Medical Devices in Europe, including classification Rule 11 for software, which has caused significant discussions among European regulators.
View Article and Find Full Text PDFTransl Psychiatry
January 2025
Department of Radiology, Shenzhen Nanshan People's Hospital, Taoyuan AVE 89, Nanshan district, Shenzhen, 518000, People's Republic of China.
At least 227 combinations of symptoms meet the criteria for Major Depressive Disorder (MDD). However, in clinical practice, patients consistently present symptoms in a regular rather than random manner, and the neural basis underlying the MDD subtypes remains unclear. To help clarify the neural basis, patients with MDD were clustered by symptom combinations to investigate the neural underpinning of each subtype using functional resonance imaging (fMRI).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!